Lexaria Bioscience Corp. (NASDAQ: LEXX): A Review of Its Research Developments
- Lexaria Bioscience, the global innovator behind DehydraTECH drug delivery technology, has continuously focused on research into its patented technology
- The company has conducted both in vitro testing and in vivo animal and human testing to evaluate the ability of DehydraTECH to improve the delivery of various APIs (active pharmaceutical ingredients)
- Lexaria has multiple other studies lined up aimed at building sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation
As it moves toward national and international implementation and commercialization of its patented DehydraTECH(TM) drug delivery technology, Lexaria Bioscience (NASDAQ: LEXX) is aware of the need to continuously advance its understanding of the technology’s capabilities and potential applications. This informs the company’s long-held commitment to its applied research and development (“R&D”) programs, which are exclusively designed to “reduce future risks of both commercial and regulatory failure by identifying weaknesses as early as possible; and to enhance the likelihood of future commercial and regulatory success by thoroughly understanding strengths and weaknesses, also as early as possible” (https://nnw.fm/J7gJh).
Lexaria’s DehydraTECH technology combines a lipophilic active pharmaceutical ingredient (“API”) with a carrier particle, then it is dehydrated and finally rendered as a liquid or powder. Through the years, Lexaria has proven that DehydraTECH results in additional improvements, including speed of onset, increased brain absorption, increased bioavailability, and reduced drug administration costs, thanks to extensive research the company has continuously undertaken since 2015.
So far, the research journey has involved a series of controlled and well-designed in vitro pre-clinical testing and in vivo animal and human clinical studies, as well as all-encompassing molecular characterization investigations, which have been completed on APIs such as antiviral drugs, cannabinoids, nicotine and nicotine analogs, PDE5 inhibitors and non-steroidal anti-inflammatory drugs (“NSAIDs”).
The company’s in vitro pre-clinical test, an absorption study, was performed to investigate unidirectional cannabidiol (“CBD”) permeability using a human epi-intestinal tissue model with multiple formulations in the presence of simulated intestinal fluid. According to Lexaria, the study evidenced a 325% and 499%, on average, in intestinal tissue permeability compared to two control groups.
Lexaria has also undertaken extensive clinical research starting in 2016. Multiple independent, well-designed, and controlled human studies conducted between 2016 and 2017, for example, corroborated the results from the in vitro studies. Since then, the company has undertaken numerous other studies evaluating the performance of various APIs processed using the DehydraTECH technology. For instance, Lexaria has investigated DehydraTECH-CBD as a potential treatment for hypertension and heart disease in multiple human studies, DehydraTECH-processed nicotine (animal study), and antivirals.
“Performance of total bioabsorption (directly and indirectly through surrogate biomarkers), blood-brain-barrier delivery characteristics, rapidity of onset, consumer appeal, metabolite production (an indication of first-pass liver bypass), and quality of effectiveness have all been quantified,” Lexaria’s website says of the investigation parameters (https://nnw.fm/vJcUG).
Still, Lexaria is unrelenting in its pursuit of comprehensive datasets that would answer many questions the company expects to face from potential commercial partners or regulators and is, in fact, expanding its research. Last month, Lexaria kicked off an animal study to evaluate DehydraTECH-CBD as a potential treatment to inhibit seizure activity (https://nnw.fm/FBMVE), the first in a series of additional planned animal studies tentatively set to commence this year (https://nnw.fm/br6CJ). Others include:
- HOR-A22-1: an animal study to evaluate DehydraTECH’s ability to improve the delivery characteristics of estrogen
- DEM-A22-1: an efficacy study to investigate DehydraTECH-CBD with and without nicotine for the potential treatment of dementia
- RHEUM-A22-1: an efficacy study to evaluate the ability of DehydraTECH-CBD to potentially impact the treatment of rheumatoid disease
- DIAB-A22-1: an efficacy study to investigate DehydraTECH-CBD’s ability to potentially affect the treatment of diabetes
“DehydraTECH is not an EVOLUTION of existing technology – it is a REVOLUTIONARY new drug delivery platform. Expecting entire industries to change overnight to adopt a revolutionary process is not realistic: it takes time, evidence, and a lot of positive results to overcome industry inertia. We have long been hopeful that, before the end of 2022, we will have built sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation,” Lexaria CEO Chris Bunka wrote in a recent letter to shareholders.
And with the planned and ongoing human and animal studies, Lexaria hopes to achieve precisely this.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria Bioscience, the global innovator behind DehydraTECH drug delivery technology, has continuously focused on research into its patented technology
- The company has conducted both in vitro testing and in vivo animal and human testing to evaluate the ability of DehydraTECH to improve the delivery of various APIs (active pharmaceutical ingredients)
- Lexaria has multiple other studies lined up aimed at building sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation
As it moves toward national and international implementation and commercialization of its patented DehydraTECH(TM) drug delivery technology, Lexaria Bioscience (NASDAQ: LEXX) is aware of the need to continuously advance its understanding of the technology’s capabilities and potential applications. This informs the company’s long-held commitment to its applied research and development (“R&D”) programs, which are exclusively designed to “reduce future risks of both commercial and regulatory failure by identifying weaknesses as early as possible; and to enhance the likelihood of future commercial and regulatory success by thoroughly understanding strengths and weaknesses, also as early as possible” (https://nnw.fm/J7gJh).
Lexaria’s DehydraTECH technology combines a lipophilic active pharmaceutical ingredient (“API”) with a carrier particle, then it is dehydrated and finally rendered as a liquid or powder. Through the years, Lexaria has proven that DehydraTECH results in additional improvements, including speed of onset, increased brain absorption, increased bioavailability, and reduced drug administration costs, thanks to extensive research the company has continuously undertaken since 2015.
So far, the research journey has involved a series of controlled and well-designed in vitro pre-clinical testing and in vivo animal and human clinical studies, as well as all-encompassing molecular characterization investigations, which have been completed on APIs such as antiviral drugs, cannabinoids, nicotine and nicotine analogs, PDE5 inhibitors and non-steroidal anti-inflammatory drugs (“NSAIDs”).
The company’s in vitro pre-clinical test, an absorption study, was performed to investigate unidirectional cannabidiol (“CBD”) permeability using a human epi-intestinal tissue model with multiple formulations in the presence of simulated intestinal fluid. According to Lexaria, the study evidenced a 325% and 499%, on average, in intestinal tissue permeability compared to two control groups.
Lexaria has also undertaken extensive clinical research starting in 2016. Multiple independent, well-designed, and controlled human studies conducted between 2016 and 2017, for example, corroborated the results from the in vitro studies. Since then, the company has undertaken numerous other studies evaluating the performance of various APIs processed using the DehydraTECH technology. For instance, Lexaria has investigated DehydraTECH-CBD as a potential treatment for hypertension and heart disease in multiple human studies, DehydraTECH-processed nicotine (animal study), and antivirals.
“Performance of total bioabsorption (directly and indirectly through surrogate biomarkers), blood-brain-barrier delivery characteristics, rapidity of onset, consumer appeal, metabolite production (an indication of first-pass liver bypass), and quality of effectiveness have all been quantified,” Lexaria’s website says of the investigation parameters (https://nnw.fm/vJcUG).
Still, Lexaria is unrelenting in its pursuit of comprehensive datasets that would answer many questions the company expects to face from potential commercial partners or regulators and is, in fact, expanding its research. Last month, Lexaria kicked off an animal study to evaluate DehydraTECH-CBD as a potential treatment to inhibit seizure activity (https://nnw.fm/FBMVE), the first in a series of additional planned animal studies tentatively set to commence this year (https://nnw.fm/br6CJ). Others include:
- HOR-A22-1: an animal study to evaluate DehydraTECH’s ability to improve the delivery characteristics of estrogen
- DEM-A22-1: an efficacy study to investigate DehydraTECH-CBD with and without nicotine for the potential treatment of dementia
- RHEUM-A22-1: an efficacy study to evaluate the ability of DehydraTECH-CBD to potentially impact the treatment of rheumatoid disease
- DIAB-A22-1: an efficacy study to investigate DehydraTECH-CBD’s ability to potentially affect the treatment of diabetes
“DehydraTECH is not an EVOLUTION of existing technology – it is a REVOLUTIONARY new drug delivery platform. Expecting entire industries to change overnight to adopt a revolutionary process is not realistic: it takes time, evidence, and a lot of positive results to overcome industry inertia. We have long been hopeful that, before the end of 2022, we will have built sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation,” Lexaria CEO Chris Bunka wrote in a recent letter to shareholders.
And with the planned and ongoing human and animal studies, Lexaria hopes to achieve precisely this.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
